Switch theme
Sign up to access all valuation multiples
Hugel Inc is a biopharmaceutical company. It is in the business of manufacturing of biopharmaceuticals. The company's primary products are Botulinum toxin, Hyaluronic acid filler, and Cosmetics. It develops and promotes its products under the brand name of Wellage. The firm has manufacturing facilities in Shinbuk and Geodu.
2001
n/a
LTM Revenue $294M
LTM EBITDA $147M
$2.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Hugel has a last 12-month revenue (LTM) of $294M and a last 12-month EBITDA of $147M.
In the most recent fiscal year, Hugel achieved revenue of $271M and an EBITDA of $132M.
Hugel expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Hugel valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $294M | XXX | $271M | XXX | XXX | XXX |
| Gross Profit | $227M | XXX | $209M | XXX | XXX | XXX |
| Gross Margin | 77% | XXX | 77% | XXX | XXX | XXX |
| EBITDA | $147M | XXX | $132M | XXX | XXX | XXX |
| EBITDA Margin | 50% | XXX | 49% | XXX | XXX | XXX |
| EBIT | $136M | XXX | $121M | XXX | XXX | XXX |
| EBIT Margin | 46% | XXX | 45% | XXX | XXX | XXX |
| Net Profit | $111M | XXX | $98.7M | XXX | XXX | XXX |
| Net Margin | 38% | XXX | 36% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Hugel's stock price is KRW 332000 (or $241).
Hugel has current market cap of KRW 3.57T (or $2.6B), and EV of KRW 3.14T (or $2.3B).
See Hugel trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.3B | $2.6B | XXX | XXX | XXX | XXX | $9.17 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Hugel has market cap of $2.6B and EV of $2.3B.
Hugel's trades at 8.4x EV/Revenue multiple, and 17.3x EV/EBITDA.
Equity research analysts estimate Hugel's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hugel has a P/E ratio of 23.3x.
See valuation multiples for Hugel and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.6B | XXX | $2.6B | XXX | XXX | XXX |
| EV (current) | $2.3B | XXX | $2.3B | XXX | XXX | XXX |
| EV/Revenue | 7.8x | XXX | 8.4x | XXX | XXX | XXX |
| EV/EBITDA | 15.5x | XXX | 17.3x | XXX | XXX | XXX |
| EV/EBIT | 16.7x | XXX | 18.9x | XXX | XXX | XXX |
| EV/Gross Profit | 10.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 23.3x | XXX | 26.3x | XXX | XXX | XXX |
| EV/FCF | 24.3x | XXX | 27.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHugel's last 12 month revenue growth is 21%
Hugel's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Hugel's rule of 40 is 67% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Hugel's rule of X is 102% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Hugel and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 21% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Margin | 50% | XXX | 49% | XXX | XXX | XXX |
| EBITDA Growth | 27% | XXX | 25% | XXX | XXX | XXX |
| Rule of 40 | 67% | XXX | 69% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 102% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 15% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 32% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hugel acquired XXX companies to date.
Last acquisition by Hugel was XXXXXXXX, XXXXX XXXXX XXXXXX . Hugel acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Hugel founded? | Hugel was founded in 2001. |
| Where is Hugel headquartered? | Hugel is headquartered in South Korea. |
| Is Hugel publicy listed? | Yes, Hugel is a public company listed on KRX. |
| What is the stock symbol of Hugel? | Hugel trades under 145020 ticker. |
| When did Hugel go public? | Hugel went public in 2015. |
| Who are competitors of Hugel? | Similar companies to Hugel include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Hugel? | Hugel's current market cap is $2.6B |
| What is the current revenue of Hugel? | Hugel's last 12 months revenue is $294M. |
| What is the current revenue growth of Hugel? | Hugel revenue growth (NTM/LTM) is 21%. |
| What is the current EV/Revenue multiple of Hugel? | Current revenue multiple of Hugel is 7.8x. |
| Is Hugel profitable? | Yes, Hugel is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Hugel? | Hugel's last 12 months EBITDA is $147M. |
| What is Hugel's EBITDA margin? | Hugel's last 12 months EBITDA margin is 50%. |
| What is the current EV/EBITDA multiple of Hugel? | Current EBITDA multiple of Hugel is 15.5x. |
| What is the current FCF of Hugel? | Hugel's last 12 months FCF is $94.2M. |
| What is Hugel's FCF margin? | Hugel's last 12 months FCF margin is 32%. |
| What is the current EV/FCF multiple of Hugel? | Current FCF multiple of Hugel is 24.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
